1887
banner image
No data available.
Please log in to see this content.
You have no subscription access to this content.
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.
The full text of this article is not currently available.
oa
A clinical data validated mathematical model of prostate cancer growth under intermittent androgen suppression therapy
Rent:
Rent this article for
Access full text Article
/content/aip/journal/adva/2/1/10.1063/1.3697848
1.
1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M. Thun, CA Cancer J. Clin. 59, 225 (2009).
http://dx.doi.org/10.3322/caac.20006
2.
2. R. Berges, J. Vukanovic, J. Epstein, M. CarMichel, L. Cisek, D. Johnson, R. Veltri, P. Walsh, and J. Isaacs, Clin. Cancer Res. 1, 473 (1995).
3.
3. C. Heinlein and C. Chang, Endocrine Rev. 25, 276 (2004).
http://dx.doi.org/10.1210/er.2002-0032
4.
4. N. Craft, C. Chhor, C. Tran, A. Belldegrun, J. DeKernion, O. Witte, J. Said, R. Reiter, and C. L. Sawyers, Cancer Res. 59, 5030 (1999).
5.
5. N. Sharifi, J. Gulley, and W. Dahut, Jama 294, 238 (2005).
http://dx.doi.org/10.1001/jama.294.2.238
6.
6. U. Tunn, BJU Int. 99, 19 (2007).
http://dx.doi.org/10.1111/j.1464-410X.2007.06596.x
7.
7. L. Klotz, H. Herr, M. Morse, and W. Whitmore Jr., Cancer 58, 2546 (1986).
http://dx.doi.org/10.1002/1097-0142(19861201)58:11<2546::AID-CNCR2820581131>3.0.CO;2-N
8.
8. K. Akakura, N. Bruchovsky, S. Goldenberg, P. Rennie, A. Buckley, and L. Sullivan, Cancer 71, 2782 (1993).
http://dx.doi.org/10.1002/1097-0142(19930501)71:9<2782::AID-CNCR2820710916>3.0.CO;2-Z
9.
9. J. Crook, E. Szumacher, S. Malone, S. Huan, and R. Segal, Urology 53, 530 (1999).
http://dx.doi.org/10.1016/S0090-4295(98)00547-0
10.
10. S. Goldenberg, N. Bruchovsky, M. Gleave, L. Sullivan, and K. Akakura, Urology 45, 839 (1995).
http://dx.doi.org/10.1016/S0090-4295(99)80092-2
11.
11. N. Bruchovsky, L. Klotz, J. Crook, N. Phillips, J. Abersbach, and S. Goldenberg, Clin. Cancer Rev. 2, 82 (2008).
http://dx.doi.org/10.3816/CCU.2008.n.013
12.
12. F. Schröder, Eur. J. Cancer 45, 402 (2009).
http://dx.doi.org/10.1016/S0959-8049(09)70065-6
13.
13. T. Jackson, Discrete Cont. Dyn. Syst. Ser. B 4, 187 (2004).
http://dx.doi.org/10.3934/dcdsb.2004.4.187
14.
14. A. Ideta, G. Tanaka, T. Takeuchi, and K. Aihara, J. Nonlinear Sci. 18, 593 (2008).
http://dx.doi.org/10.1007/s00332-008-9031-0
15.
15. M. Grossmann, H. Huang, and D. Tindall, J. Nat. Cancer Inst. 93, 1687 (2001).
http://dx.doi.org/10.1093/jnci/93.22.1687
16.
16. Y. Hirata, N. Bruchovsky, and K. Aihara, J. Theor. Biol. 264, 517 (2010).
http://dx.doi.org/10.1016/j.jtbi.2010.02.027
17.
17. Y. Hirata, M. di Bernardo, N. Bruchovsky, and K. Aihara, Chaos 20, 045125 (2010).
http://dx.doi.org/10.1063/1.3526968
18.
18. G. Dimonte, J. Theor. Biol. 264, 420 (2010).
http://dx.doi.org/10.1016/j.jtbi.2010.02.023
19.
19. S. Eikenberry, J. Nagy, and Y. Kuang, Biology Direct 5 (2010).
http://dx.doi.org/10.1186/1745-6150-5-24
20.
20. K. Swanson, L. True, D. Lin, K. Buhler, R. Vessella, and J. Murray, Am. J. Pathol. 158, 2195 (2001).
http://dx.doi.org/10.1016/S0002-9440(10)64691-3
21.
21.See supplementary material at http://dx.doi.org/10.1063/1.3697848 for a formulation of the Ideta model, parameter range tables, and interpolated androgen data plots. [Supplementary Material]
22.
22. M. Droop, J. Mar. Biol. Assoc. UK 48, 689 (1968).
http://dx.doi.org/10.1017/S0025315400019238
23.
23. A. Packer, Y. Li, T. Andersen, H. Qiang, Y. Kuang, and M. Sommerfeld, Bioresource Tech. 102, 111 (2011).
http://dx.doi.org/10.1016/j.biortech.2010.06.029
24.
24. M.-E. Taplin and S. Balk, J. Cellular Biochem. 91, 483 (2004).
http://dx.doi.org/10.1002/jcb.10653
25.
25. K. Lamont and D. Tindall, Mol. Endocrinol. 25, 897 (2011).
http://dx.doi.org/10.1210/me.2010-0469
26.
26. B. Feldman and D. Feldman, Nat. Rev. Cancer 1, 34 (2001).
http://dx.doi.org/10.1038/35094009
27.
27. N. Bruchovsky, L. Klotz, J. Crook, and S. Goldenberg, Cancer 109 (2007).
http://dx.doi.org/10.1002/cncr.22464
http://aip.metastore.ingenta.com/content/aip/journal/adva/2/1/10.1063/1.3697848
Loading
/content/aip/journal/adva/2/1/10.1063/1.3697848
Loading

Data & Media loading...

Loading

Article metrics loading...

/content/aip/journal/adva/2/1/10.1063/1.3697848
2012-03-19
2014-12-19

Abstract

Prostate cancer is commonly treated by a form of hormone therapy called androgen suppression. This form of treatment, while successful at reducing the cancercell population, adversely affects quality of life and typically leads to a recurrence of the cancer in an androgen-independent form. Intermittent androgen suppression aims to alleviate some of these adverse affects by cycling the patient on and off treatment. Clinical studies have suggested that intermittent therapy is capable of maintaining androgen dependence over multiple treatment cycles while increasing quality of life during off-treatment periods. This paper presents a mathematical model of prostate cancer to study the dynamics of androgen suppression therapy and the production of prostate-specific antigen (PSA), a clinical marker for prostate cancer. Preliminary models were based on the assumption of an androgen-independent (AI) cell population with constant net growth rate. These models gave poor accuracy when fitting clinical data during simulation. The final model presented hypothesizes an AI population with increased sensitivity to low levels of androgen. It also hypothesizes that PSA production is heavily dependent on androgen. The high level of accuracy in fitting clinical data with this model appears to confirm these hypotheses, which are also consistent with biological evidence.

Loading

Full text loading...

/deliver/fulltext/aip/journal/adva/2/1/1.3697848.html;jsessionid=bh612fkqo6529.x-aip-live-03?itemId=/content/aip/journal/adva/2/1/10.1063/1.3697848&mimeType=html&fmt=ahah&containerItemId=content/aip/journal/adva
true
true
This is a required field
Please enter a valid email address
752b84549af89a08dbdd7fdb8b9568b5 journal.articlezxybnytfddd
Scitation: A clinical data validated mathematical model of prostate cancer growth under intermittent androgen suppression therapy
http://aip.metastore.ingenta.com/content/aip/journal/adva/2/1/10.1063/1.3697848
10.1063/1.3697848
SEARCH_EXPAND_ITEM